ConductScience.org, home

Comparison · NCT01799993-1bb20dbf

Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Organ Failure

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Organ Failure. Trial comparisons, record NCT01799993-1bb20dbf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01799993-1bb20dbf

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1950.1570.24wilson
Risk in group 20.1870.150.23wilson
Risk difference, group 1 minus group 20.00884-0.0490.0667newcombe hybrid score
Risk ratio, group 1 over group 21.050.7741.42log
Odds ratio, group 1 over group 21.060.7291.54log
Number needed to treat, for one more participant with the outcome on Amikacin Inhale (BAY41-6551) than on Placebo113from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Amikacin Inhale (BAY41-6551)Participants received 400 mg (3.2 mL) aerosolized Amikacin (BAY41-6551) solution every 12 hours via Pulmonary Drug Delivery System (PDDS) Clinical from Day 1 to Day 10.69353OG000
Group 2PlaceboParticipants received 3.2 mL aerosolized placebo solution every 12 hours via PDDS Clinical from Day 1 to Day 10.67359OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Number of Participants With Organ Failure
Description
The overall number of participants with any organ failure was summarized for each treatment group. Organ failure was defined by a specific organ type and by a collection of MedDRA version 20.0 preferred terms that were determined by the sponsor's clinical team. A participant with multiple AEs within a system organ class or preferred term is counted a single time for that system organ class (SOC) or preferred term.
Time frame
Up to 7 days after the end of study treatment
Population
ITT for Safety population

Source ClinicalTrials.gov

Trial

Title
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
NCT number
NCT01799993
Phases
PHASE3
Conditions
Pneumonia, Bacterial
Interventions
Amikacin Inhalation Solution (BAY41-6551), Aerosolized Placebo
Lead sponsor
Bayer
Results first posted
2018-06-26

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01799993-1bb20dbf